

SHORT TAKE

Age-related changes in human hematopoietic stem/progenitor cells

Klaudia Kuranda,^{1,2} Jacques Vargaftig,³ Philippe de la Rochere,^{1,2} Christine Dosquet,^{1,2,4} Dominique Charron,^{1,2} Florence Bardin,⁵ Cecile Tonnelles,⁵ Dominique Bonnet³ and Michele Goodhardt^{1,2}

¹INSERM UMRS 940, Paris, France

²Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France

³Hematopoietic Stem Cell Laboratory, Cancer Research UK London Research Institute, London, UK

⁴Département de Biothérapies, Hôpital Saint-Louis, AP-HP; Paris, France

⁵Institut Paoli-Calmettes, Centre de Thérapie Cellulaire et Génique, Marseille, France

Summary

Adult stem cells are critical for maintaining cellular homeostasis throughout life, yet the effects of age on their regenerative capacity are poorly understood. All lymphoid and myeloid blood cell lineages are continuously generated from hematopoietic stem cells present in human bone marrow. With age, significant changes in the function and composition of mature blood cells are observed. In this study, we report that age-related changes also occur in the human hematopoietic stem cell compartment. We find that the proportion of multipotent CD34⁺CD38[−] cells increases in the bone marrow of elderly (>70 years) individuals. CD34⁺CD38⁺CD90[−]CD45RA^{+/−}CD10[−] and CD34⁺CD33⁺ myeloid progenitors persist at the same level in the bone marrow, while the frequency of early CD34⁺CD38[−]CD90[−]CD45RA⁺CD10⁺ and committed CD34⁺CD19⁺ B-lymphoid progenitors decreases with age. In contrast to mice models of aging, transplantation experiments with immunodeficient NOD/SCID/IL-2R γ null (NSG) mice showed that the frequency of NSG repopulating cells does not change significantly with age, and there is a decrease in myeloid lineage reconstitution. An age-related decrease in the capacity of CD34⁺ cells to generate myeloid cells was also seen in colony-forming assays *in vitro*. Thus, with increasing age, human hematopoietic

stem/progenitor cells undergo quantitative changes as well as functional modifications.

Key words: aging; B-lymphopoiesis; hematopoietic stem cells; myelopoiesis; xenotransplantation.

Introduction

Aging is accompanied by a decline in immune responses (for review see (Min *et al.*, 2005)) and a higher rate of unexplained anemia (Guralnik *et al.*, 2004). These age-related changes could be because of either a general decrease in bone marrow (BM) cellularity (Ogawa *et al.*, 2000; Muschler *et al.*, 2001) or impaired hematopoietic stem cell (HSC) function. Animal models have led to the generally held idea that with age, there is an increase in the number of primitive HSC with decreased repopulating capacity and biased myeloid/lymphoid potential (for review see (Waterstrat & Van Zant, 2009)). These results are based primarily on the study of C57BL/6 mice; however, strain specific differences have been reported as to the impact of age on HSC numbers (Chen *et al.*, 2000). Furthermore, in the rhesus monkey, a decrease in HSC is observed with age and unlike mouse models, aging results in a decrease in myelopoiesis, while lymphopoiesis remains intact (Lee *et al.*, 2005).

In humans, only fragmentary and contradictory information is available concerning age-related changes in HSC (Waterstrat *et al.*, 2008; Taraldsrud *et al.*, 2009; Beerman *et al.*, 2010). One study (Chatta *et al.*, 1993) suggested that the proportion of HSC and in particular myeloid progenitors in mononucleated cells was the same in young and elderly adults but the generation of mixed granulocyte–macrophage colonies decreased with age (Marley *et al.*, 1999). Some studies concerning B-lymphopoiesis indicate a decrease in B-cell progenitors in the BM with age (Rego *et al.*, 1998; McKenna *et al.*, 2001), while others found no change (Rossi *et al.*, 2003). Here, we report that although the number of phenotypic CD34⁺CD38[−] multipotent progenitor cells in human BM increases with age, there is no change in stem cell repopulating activity. Furthermore, the capacity to generate B-cell progenitors and myeloid cells as measured by both *in vivo* and *in vitro* assays is impaired.

Results and discussion

To investigate the effects of aging on human HSC, we first performed a phenotypic analysis of BM of healthy individuals, between the ages of 14 and 92 years ($n = 48$). These experiments showed that while the proportion of total BM CD34⁺ cells remained stable with age, there was a significant increase in

Correspondence

Michele Goodhardt, Unité INSERM U940, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, 1, Avenue Claude Vellefaux, 75010, Paris, France. Tel.: +33 (0)142494889; fax: +33 (0)142494641; e-mail: michele.goodhardt@univ-paris-diderot.fr

Accepted for publication 29 December 2010




Fig. 1 Age-related changes in the frequency of hematopoietic progenitors in human bone marrow (BM). (A) Frequency of hematopoietic stem cell (HSC), multipotent progenitors (MPP) and multilymphoid progenitors (MLP) in BM mononuclear cells (MNC) isolated from young (< 40 year old; open circles) and elderly (> 70 year old; closed circles) individuals. * $P < 0.006$; ** $P < 0.005$; Mann-Whitney test. Bar = mean. Phenotype of cell populations and isolation procedure are shown below the graph and in Fig. S3. (B) Frequency of committed progenitors in BM MNC. B/NK (CD34⁺CD38⁺CD90⁻CD45RA⁺CD10⁺ cells); B-committed (CD34⁺CD38⁺CD90⁻CD45RA⁺CD10⁻) and committed myeloid (CD34⁺CD33⁺) progenitors. * $P < 0.02$; ** $P < 0.01$; Mann-Whitney test. Bar = mean.

the number of multipotent CD34⁺CD38⁻ cells (Fig. 1). Early (CD34⁺CD38⁺CD90⁻CD45RA⁺CD10⁻) and committed (CD34⁺CD33⁺) myeloid progenitors persisted at the same level; however, the frequency of B/NK precursors (CD34⁺CD38⁺CD90⁻CD45RA⁺CD10⁺) and committed B-lymphoid progenitors (CD34⁺CD19⁺) decreases with age (Fig. 1B). Notably, total CD19⁺ cells in BM of elderly individuals returned to levels observed in young BM (Fig. S1).

We next compared the repopulating capacity of CD34⁺ cells isolated from young (15–29 year, $n = 6$), middle aged (49–68 year, $n = 6$), and elderly (70–92 year, $n = 4$) individuals after injection of 10^5 cells into NOD/SCID/interleukin-2 receptor γ chain-null (NSG) mice. Twelve weeks after injection, all mice were engrafted, and the level of human chimerism was similar for all age-groups (Table S1). Limiting doses of cells (0.5×10^5 , 0.1×10^5 , and 0.05×10^5 cells) from young (14–25 year, $n = 3$) and elderly (83–87 year, $n = 3$) individuals (Table S2) showed no significant differences in either the level of human chimerism (Fig. 2A) or the frequency of NSG repopulating cells (Fig. 2B). However, CD34⁺ cells from elderly individuals generated different proportions of myeloid and B-lymphoid cells in murine BM. We found a 5-fold decrease in myeloid cells, while B-lineage reconstitution remained the same (Fig. 2C). Colony-

forming assays on methylcellulose confirmed the decrease in the capacity to generate various myeloid cells with age (Fig. 2D and Fig. S2). Analysis of B-lymphopoiesis by limiting dilution assays on MS-5 stromal cells showed a decrease in the frequency of B-cell progenitors in CD34⁺ cells from elderly individuals (Fig. 2E) and maintained capacity to generate B-cells (Fig. 2F), in agreement with the phenotypic BM analyses (Fig. 1B and S1).

Collectively, our results indicate that the increased frequency of phenotypic CD34⁺CD38⁻ multipotent progenitor cells in human BM with age is not associated with increased NSG repopulating activity, but with a decreased capacity to generate B-cell progenitors and myeloid lineage cells. While further experiments are necessary to understand the mechanisms underlying these observations, this study provides evidence of quantitative and qualitative age-related changes in human hematopoietic stem/progenitor populations.

Experimental procedures

Cells

BM cells were isolated from young (10–37 year; mean = 23 year; $n = 24$; males 14/females 10) HSC allograft donors or




Fig. 2 Effects of age on myeloid and B-lymphoid potential of CD34⁺ stem/progenitor cells. Multilineage engraftment (A), frequency of NOD/SCID/IL-2R γ null (NSG) repopulating cells (B) and lineage-specific reconstitution in NSG mice (C). Limiting doses (0.5×10^5 , 0.1×10^5 and 0.05×10^5) of CD34⁺ cells from young (14–25 year; $n = 3$) and elderly (83–87 year; $n = 3$) individuals were injected intravenously into NSG mice (for details see Table S2 and Fig. S4). Twelve weeks after injections, human chimerism in murine bone marrow (BM) was measured by FC analysis and the frequency of NSG repopulating cells (NRC) was calculated using L-Cal software; $*P < 0.01$; Mann–Whitney Test. (D) The capacity of CD34⁺ cells isolated from young (10–37 year, mean = 26 year, $n = 4$) and elderly (71–89 year, mean = 77 year, $n = 11$) individuals to generate myeloid colonies was determined by *in vitro* methylcellulose assays and is significantly different $P < 0.006$; Student's *t*-test. Bar = mean. (E) The frequency of B-lymphoid progenitors in CD34⁺ cells isolated from young (10–37 year, mean = 21 year, $n = 3$) and elderly (71–89 year, mean = 77 year, $n = 7$) individuals was determined by *in vitro* limiting dilution assay on MS-5 stromal cells and was significantly different $P < 0.04$; Student's *t*-test. Bar = mean. (F) The capacity of CD34⁺ cells isolated from young (10–37 year; mean = 21 year; $n = 3$) and elderly (71–89 year; mean = 77 year; $n = 7$) individuals to generate B-cells *in vitro* was measured as the percent of CD34⁺CD19⁺ cells in hCD45⁺ cells after 4-week culture. Histograms are means \pm SD.

from middle age (49–68 year; mean = 57 year; $n = 6$; males 4/females 2) and elderly (69–92 year; mean = 78 year; $n = 55$; males 16/females 39) individuals free of hematopoietic or inflammatory disease undergoing hip replacement. Donors signed informed consent, and this study has been approved by the IRB of Paris North Hospitals. Mononuclear cells (MNC) were harvested using a Ficoll gradient. CD34⁺ cells were isolated with CD34 MicroBead kit (Milenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer's protocol.

Phenotyping

Stainings were performed using antibodies from Becton Dickinson as described in Fig. S3 for cytofluorometric analysis of hematopoietic progenitors in human bone marrow (Doulatov *et al.*, 2010) and in Fig. S4 for analysis of human chimerism in xenotransplantation experiments. Flow cytometry (FC) was performed using BD-FACS Canto II, and results were analyzed using Diva Software 6.1.2.

In vitro assays

To measure the generation of myeloid colonies, CD34⁺ cells (2500 cells per mL) were seeded in methylcellulose medium (HSC005; R&D Systems, Lille, France) and colonies were counted after 12 days. Cultures supporting B-lymphopoiesis were performed in 96-well plates on a monolayer of MS-5 cells in RPMI1640-GlutaMax medium (Gibco, Cergy Pontoise, France) with 10% fetal bovine serum (HyClone) without added cytokines (Nishihara et al., 1998). The capacity of CD34⁺ cells to generate B-cells was measured as the percentage of CD34⁺CD19⁺ cells among hCD45⁺ cells after 4 weeks in cultures seeded with 100 cells. To measure the frequency of B-lymphoid progenitors, limiting dilutions of CD34⁺ cells (250, 150, 100, 50 cells per well) were performed. Frequencies were estimated using L-Calc (StemSoft Software, Vancouver BC, Canada) based on the numbers of wells containing human B-cells (CD45⁺CD19⁺CD33⁻CD34⁻). Forty-eight wells were analyzed per cell concentration.

Xenotransplantation

Eight-week-old NOD/SCID/interleukin-2 receptor γ chain-null mice (Shultz et al., 2005) (Jackson Laboratories, Kent, England) were housed at CRUK and Institute Paoli-Calmettes animal care facilities in accordance with institutional guidelines. Sublethally irradiated animals were injected intravenously with hCD34⁺ cells. Twelve-week posttransplant engraftment in murine BM was assessed by FC analysis. Threshold engraftment was set at 0.01% of hCD45⁺ cells comprising at least 1% of both CD19⁺ and CD33⁺ cells. Frequency of NSG repopulating cells was estimated based on limiting dilution assays using L-Calc (StemSoft Software).

Acknowledgments

We thank R. Traineau, P. Richard and G. Socié from Saint-Louis Hospital as well as D. Hannouche and the Orthopedic Unit of Lariboisière Hospital in Paris for providing bone marrow samples. We also thank I. Kuzniak for technical assistance. This research was funded by the Institut National de la Santé et de la Recherche Médicale, INCA, Fondation de France, and Lejeune Foundation to M.G. DB was supported by Cancer Research UK.

Disclosure of conflicts of interest

The authors declare no competing financial interests.

Author contributions

Klaudia Kuranda was involved in manuscript writing, conception and design, data analysis and interpretation, collection and assembly of data. Jacques Vargaftig, Philippe de la Rochere and Florence Bardin assisted with the collection of data. Dominique

Charron was the head of department and supported the study. Christine Dosquet was involved in the final approval of manuscript. Cecile Tonnelle provided the study material and was involved in data interpretation. Dominique Bonnet assisted with the provision of study material, data analysis and interpretation, collection of data, final approval of manuscript. Michele Goodhardt was involved in the conception and design, data interpretation and manuscript writing.

References

- Beerman I, Maloney WJ, Weissmann IL, Rossi DJ (2010) Stem cells and the aging hematopoietic system. *Curr. Opin. Immunol.* **22**, 500–506.
- Chatta GS, Andrews RG, Rodger E, Schrag M, Hammond WP, Dale DC (1993) Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. *J. Gerontol.* **48**, M207–212.
- Chen J, Astle CM, Harrison DE (2000) Genetic regulation of primitive hematopoietic stem cell senescence. *Exp. Hematol.* **28**, 442–450.
- Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE (2010) Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. *Nat. Immunol.* **11**, 585–593.
- Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. *Blood* **104**, 2263–2268.
- Lee CC, Fletcher MD, Tarantal AF (2005) Effect of age on the frequency, cell cycle, and lineage maturation of rhesus monkey (*Macaca mulatta*) CD34⁺ and hematopoietic progenitor cells. *Pediatr. Res.* **58**, 315–322.
- Marley SB, Lewis JL, Davidson RJ, Roberts IA, Dokal I, Goldman JM, Gordon MY (1999) Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. *Br. J. Haematol.* **106**, 162–166.
- McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH (2001) Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. *Blood* **98**, 2498–2507.
- Min H, Montecino-Rodriguez E, Dorshkind K (2005) Effects of aging on early B- and T-cell development. *Immunol. Rev.* **205**, 7–17.
- Muschler GF, Nitto H, Boehm CA, Easley KA (2001) Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. *J. Orthop. Res.* **19**, 117–125.
- Nishihara M, Wada Y, Ogami K, Ebihara Y, Ishii T, Tsuji K, Ueno H, Asano S, Nakahata T, Maekawa T (1998) A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5. *Eur. J. Immunol.* **28**, 855–864.
- Ogawa T, Kitagawa M, Hirokawa K (2000) Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. *Mech. Ageing Dev.* **117**, 57–68.
- Rego EM, Garcia AB, Viana SR, Falcao RP (1998) Age-related changes of lymphocyte subsets in normal bone marrow biopsies. *Cytometry* **34**, 22–29.
- Rossi MI, Yokota T, Medina KL, Garrett KP, Comp PC, Schipul Jr AH, Kincade PW (2003) B lymphopoiesis is active throughout human life,

but there are developmental age-related changes. *Blood* **101**, 576–584.

Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J. Immunol.* **174**, 6477–6489.

Taraldsrud E, Grogard HK, Solheim S, Lunde K, Floisand Y, Arnesen H, Seljeflot I, Egeland T (2009) Age and stress related phenotypical changes in bone marrow CD34⁺ cells. *Scand. J. Clin. Lab. Invest.* **69**, 79–84.

Waterstrat A, Van Zant G (2009) Effects of aging on hematopoietic stem and progenitor cells. *Curr. Opin. Immunol.* **21**, 408–413.

Waterstrat A, Oakley EJ, Miller A, Swiderski C, Liang Y, Van Zant G (2008) Mechanisms of stem cell aging. In *Telomeres and Telomerase in Ageing, Disease, and Cancer* (KL Rudolph, ed). Berlin Heidelberg, Germany: Springer, pp. 111–140.

Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1 Engraftment efficiency in NSG mice of non-limiting doses of CD34⁺ cells (10⁵ cells per mouse) with age.

Table S2 Limiting dilution assays with CD34⁺ cells from young and elderly individuals in NSG mice.

Fig. S1 Frequency of CD19⁺ cells in human BM with age.

Fig. S2 Decreased generation of myeloid colonies from CD34⁺ cells with age.

Fig. S3 Cytofluorometric analysis of hematopoietic progenitors in human BM.

Fig. S4 Cytofluorometric analysis of B-lymphoid and myeloid lineage reconstitution in BM of NSG mice.

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.